• Sensei Biotherapeutics posted a net loss of USD 170.2 million, or USD 131.45 per share, for first-quarter 2026 versus a net loss of USD 6.9 million, or USD 5.45 per share, a year earlier.
• Operating expenses climbed to USD 170.6 million, driven by USD 133 million in acquired in-process R&D expenses tied to the Faeth Therapeutics transaction.
• R&D expense rose to USD 18 million, while G&A expense increased to USD 19.7 million, both reflecting inclusion of Faeth operations and one-time acquisition-related costs.
• Cash, cash equivalents and marketable securities totaled USD 202.8 million at March 31, up from USD 21.2 million at Dec. 31, following a USD 200 million private placement completed alongside the Faeth acquisition.
• First patient was dosed in April in a Phase 1b/2 PIKTOR trial in HR+/HER2- advanced breast cancer, while topline Phase 2 data in advanced endometrial cancer is expected in second-half 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605150730BIZWIRE_USPR_____20260515_BW710096) on May 15, 2026, and is solely responsible for the information contained therein.